GLP-1 stocks have quietly become the most consequential trade in healthcare. The category built around semaglutide and tirzepatide has rewritten the obesity treatment landscape, moved a small European country's entire GDP, and created the first trillion-dollar question in modern pharma: how big can this actually get? For investors entering the space in 2026, the two names that matter above all others are Novo Nordisk (NVO) and Eli Lilly (LLY), but the competitive field behind them is finally starting to thicken.
This guide walks through the GLP-1 market opportunity, the two incumbents, the challengers circling them, and the risks nobody talks about at the sell-side conferences. This article is for educational purposes only and does not constitute investment advice.
Market Overview
The global market for GLP-1 receptor agonists — originally developed for type 2 diabetes and now dominated by obesity indications — crossed roughly $50 billion in annual sales in 2024 and is projected by most bank analysts to reach $130–$200 billion by 2030. Goldman Sachs, Morgan Stanley, and J.P. Morgan all sit in the $150B neighborhood as a midpoint estimate. That puts GLP-1s on a trajectory to become the single largest drug class in history, eclipsing statins at their peak.
The demand story rests on three pillars. First, obesity prevalence: more than 40% of US adults and over a billion people worldwide meet the clinical threshold. Second, cardiovascular outcomes: semaglutide's SELECT trial showed a 20% reduction in major adverse cardiovascular events, converting obesity drugs from "cosmetic" to "preventive cardiology" in the eyes of payers. Third, indication expansion: sleep apnea (Zepbound already approved), chronic kidney disease (FLOW trial), heart failure (STEP-HFpEF), MASH, Alzheimer's, and addiction are all under active investigation. Each positive readout widens the addressable population.
Supply, not demand, has been the binding constraint through most of 2023–2025. That is finally loosening in 2026 as Novo and Lilly bring new fill-finish and active pharmaceutical ingredient capacity online, but the manufacturing build-out has reshaped the entire peptide supply chain (see our companion piece on peptide CDMOs and the GLP-1 manufacturing bottleneck).
Key Companies
The GLP-1 trade is effectively a duopoly with a deep bench of challengers. Market caps below reflect early-2026 levels and will move.
| Company | Ticker | Lead Asset(s) | Stage | Market Cap (approx) |
|---|---|---|---|---|
| Novo Nordisk | NVO | Semaglutide (Ozempic/Wegovy/Rybelsus), CagriSema | Marketed / Ph3 | ~$450B |
| Eli Lilly | LLY | Tirzepatide (Mounjaro/Zepbound), retatrutide, orforglipron | Marketed / Ph3 | ~$700B |
| Amgen | AMGN | MariTide (maridebart cafraglutide) | Phase 3 | ~$160B |
| Viking Therapeutics | VKTX | VK2735 (SC + oral) | Phase 2/3 | ~$6B |
| Structure Therapeutics | GPCR | Aleniglipron (oral small molecule GLP-1) | Phase 2/3 | ~$2B |
| Altimmune | ALT | Pemvidutide (GLP-1/glucagon) | Phase 2b/3 | ~$400M |
Novo Nordisk (NVO): The Danish Juggernaut
Novo Nordisk is the company that invented the modern GLP-1 category. Semaglutide — sold as Ozempic for diabetes, Wegovy for obesity, and Rybelsus as an oral tablet — generated roughly $40 billion in 2024 sales and still accounts for the majority of Novo's revenue. The company became the most valuable listed firm in Europe in 2023, briefly larger than LVMH, and its growth is so dominant that Denmark's central bank publishes economic forecasts with and without Novo's contribution.
The 2026 narrative at Novo is about three things: defending semaglutide, launching CagriSema (a cagrilintide + semaglutide combination that missed some expectations in the REDEFINE-1 readout but is still a commercial product), and scaling up own-manufacturing after the Catalent acquisition by parent Novo Holdings in late 2024 gave the company three additional fill-finish sites. The bull case is that Novo still has the deepest installed injection-pen manufacturing base and the strongest brand recognition outside the US.
Eli Lilly (LLY): The Momentum Leader
Eli Lilly is the company Wall Street has rewarded most aggressively. Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) is a dual GIP/GLP-1 agonist that has shown superior weight loss versus semaglutide in head-to-head trials (SURMOUNT-5), and the pipeline behind it is arguably the best in the industry:
- Retatrutide — a triple agonist (GIP/GLP-1/glucagon) in Phase 3 that showed 24%+ weight loss in Phase 2, the deepest numbers ever seen with a peptide drug.
- Orforglipron — a once-daily oral non-peptide GLP-1 receptor agonist that avoids the food-fasting restrictions of Rybelsus. If approved, it becomes the first truly convenient pill in the category.
- Eloralintide — an amylin agonist positioned as a potential combo partner.
Lilly's US commercial execution has been sharper than Novo's, and its Research Triangle Park expansion plus Concord, North Carolina and Lebanon, Indiana facilities are coming online just as demand spikes. The bear case is valuation — LLY trades at the highest forward multiples in big pharma and has essentially no margin for a pipeline stumble.
The Challengers
Amgen (AMGN) is advancing MariTide, a monthly-dosed GLP-1/GIP antagonist antibody-peptide conjugate. Monthly dosing is a potential differentiator if efficacy holds up in Phase 3 (readouts expected late 2026), though the Phase 2 safety profile raised some eyebrows around bone mineral density.
Viking Therapeutics (VKTX) is the classic small-cap GLP-1 story. VK2735 is a dual GIP/GLP-1 agonist with both subcutaneous and oral formulations. Phase 2 data have been impressive, and Viking is widely discussed as an acquisition target. It remains binary and volatile.
Structure Therapeutics (GPCR) is developing oral small-molecule GLP-1 receptor agonists — the same modality Lilly is chasing with orforglipron. If the category goes oral, Structure's technology could matter; if Lilly gets there first and at scale, Structure becomes a secondary player.
Altimmune (ALT) has pemvidutide, a GLP-1/glucagon dual agonist targeting both obesity and MASH (formerly NASH). The MASH angle is the interesting one — a peptide that addresses liver disease as well as weight could carve a premium niche.
The Science Under the Hood
GLP-1 is a 30-amino-acid gut peptide released by L-cells in the intestine after you eat. It slows gastric emptying, stimulates glucose-dependent insulin secretion, and signals satiety in the hypothalamus. Native GLP-1 has a half-life of about two minutes. The trick behind semaglutide and tirzepatide is a fatty-acid tail that binds reversibly to albumin in the blood, stretching the half-life to about a week — which is why these drugs are dosed weekly instead of hourly.
Tirzepatide adds a twist by also activating the GIP receptor, and retatrutide adds glucagon on top of that. Each additional receptor recruits a different arm of metabolic physiology, which is why efficacy has climbed with each generation. If you want the fundamentals, start with our beginner explainer on natural peptides in the human body.
Investment Thesis & Risks
Bull Case
- Indication expansion. Cardiovascular, kidney, sleep apnea, MASH, and Alzheimer's trials keep widening the label.
- Penetration is still low. Fewer than 15% of eligible US obesity patients are on therapy, and international markets lag further.
- Moats are real. Peptide manufacturing is hard, the regulatory bar is high, and the two leaders have spent tens of billions on capacity.
- Generic and compounding relief. Once supply normalizes, list prices drop, and insurance and Medicare coverage widens, volume should accelerate even as price falls.
Bear Case
- Patent cliffs. Semaglutide's composition-of-matter patent expires in China as early as 2026 and in the US in the 2031–2033 window depending on the formulation. Generic semaglutide in India and Brazil is already on shelves.
- Compounding gray market. US compounding pharmacies pumped out millions of doses during the shortage, establishing a price anchor far below list that may be hard to walk back.
- Oral disruption. If Lilly's orforglipron or Structure's oral programs work at scale, injectable pen sales (and margins) compress.
- Side effect surveillance. Ongoing questions around gastroparesis, pancreatitis, thyroid C-cell tumors (boxed warning), and ileus cases. No single finding has derailed the category, but a cluster event could.
- Medicare and payer pushback. CMS has begun covering Wegovy for cardiovascular risk reduction but not pure obesity. A broader coverage decision could be a tailwind; a restrictive one could cap growth.
- Valuation. LLY trades at multiples only sustainable if every pipeline asset works.
What To Watch in 2026
- Retatrutide Phase 3 readouts (TRIUMPH program). Key catalyst for LLY and for the whole category's ceiling.
- Orforglipron NDA submission and label. If fasting restrictions are light, this is a major unlock.
- MariTide Phase 3 data. Can Amgen actually break into the duopoly?
- Viking VK2735 Phase 3 initiation and any M&A headlines.
- China generic launches. The first real test of semaglutide's ex-US pricing power.
- Medicare Part D coverage decisions for obesity.
- Novo CagriSema follow-up data and any next-generation Novo asset (amycretin).
Connection to Gene Editing
Here is the angle you will not find in most GLP-1 research reports. Every GLP-1 drug on the market is a modified peptide — semaglutide and tirzepatide are still fundamentally chains of amino acids encoded, ultimately, in DNA. That makes them expensive to make and forces patients into weekly injections for life. Gene editing companies are already exploring a different path: instead of shipping the peptide, why not edit the patient's own cells to produce GLP-1 (or its analogs) endogenously?
Verve Therapeutics and other in-vivo editing pioneers have shown that base editing can durably alter metabolic genes in the liver with a single dose. A CRISPR or base editing approach to obesity — for example, knocking down GIPR or editing the GCG locus — remains speculative, but it is the logical endgame that would compress the GLP-1 category from a weekly subscription model into a one-shot therapy. That is a multi-decade threat, not a 2026 one, but it is the reason the smartest biotech investors track gene editing and peptide therapeutics as two sides of the same disease-modification problem.
Frequently Asked Questions
Q: Is Novo Nordisk or Eli Lilly the better GLP-1 stock? A: The two are not substitutes. Lilly has the stronger pipeline and momentum at the cost of a richer valuation; Novo has the deeper install base and lower multiple but a more mature lead asset and a rougher 2024–2025 stretch. Most diversified investors own both.
Q: What happens when semaglutide loses patent protection? A: Composition patents expire first in emerging markets (China as early as 2026), then in the US around 2031–2033 depending on formulation. Generic injectable peptides are harder to launch than small-molecule generics, so price erosion is usually slower than with a pill.
Q: Are compounded GLP-1s a real threat? A: They were during the FDA shortage list period, but as Novo and Lilly have scaled supply, the FDA has removed semaglutide and tirzepatide from the shortage list, which tightens the legal window for mass compounding. Gray-market suppliers persist but face growing enforcement risk.
Q: Could a smaller company actually displace Novo or Lilly? A: Not alone. The capital required to run Phase 3 obesity trials (thousands of patients, years of follow-up) and build peptide manufacturing favors incumbents. The most realistic path is acquisition — Viking Therapeutics is the name most often cited.
Q: What is the difference between Ozempic and Wegovy? A: Same molecule (semaglutide), different doses and labels. Ozempic is approved for type 2 diabetes; Wegovy is approved for chronic weight management.
